The study said that statins reduce the risk of heart transplant patients with tumors
The study found that statin therapy can help heart transplant patients to reduce the HSPE1 risk of tumor development in a very long period of time.Single center after heart transplantation in patients taking statins, study found that the incidence of each cancer is roughly reduced by half.The cumulative rate of cancer incidence in patients with heart failure at the annual meeting, MD GeorgM.Froelich of the University Hospital of Zurich, said after heart transplantation the use of statin therapy within HSPH1 eight years after 13%, without the use of statin therapy cumulative rate of cancer incidence in the postoperative period of eight years to reach 34% (P <0.003).Cohort study of patients taking statins after adjustment for age, gender, cardiomyopathy, immune therapy and cancer survival rate was 67%. Previous studies have shown that statins not only for the treatment of atherosclerosis hardening HTATIP2 effective and also have a role in the overall survival for heart transplant patients.Froelich explained, these data make the benefits of statins extend to the reason of the long-term mortality in patients after heart transplantation immunotherapy on the one hand helps the body fight transplant rejection of the donor heart implanted bring the other in turn can effective against HTRA1 cancer cells.Froelich Research Center study found that from 1985 to 2007 a total of 255 patients in the postoperative survival time of heart transplantation for at least more than one year, while at the same time of the follow-up of 42% of patients the cancer.Has recommended in the guide given to all heart transplant patients with statin use, Froelich also recommended, these results may suggest another reason for the HTRA2 occurrence of cardiac transplantation in patients with cancer,
"L consider these data alone is not sufficient to prove the existence of a true causal relationship between Strasbourg, France, University Hospital, MD GeraldRou" and on MedpageToday, he said, "Obviously, the following conclusions before need more support. But if this conclusion is true, for the treatment of heart transplant patients is a breakthrough through the the Froelich study confirmed the role of statins to reduce the occurrence of cardiac transplantation in patients with tumor very reasonable of. He pointed out that statins has pleiotropic effects, including immune adjustment, the role of cells in the matrix metalloproteinases and cancer occurred and the development of the process of apoptosis. he adds, but whether all of his statin class of drugs for differenttypes of patients, or others, such as lung transplant recipients enough to accept the strict immunosuppressive therapy in patients with this problem, is not clear.They observed data, the benefits of statins will continue for some time. 10 years of follow-up study, statin users were 10 years tumor cumulative incidence rate of the earth 18% without taking statin therapy in patients up to 39%. Patients 12 years of follow-up study, patients taking statin therapy, 10 years, tumor cumulative incidence of 22%, without taking statins and 42% between a statistically significant difference. In previous studies, patients taking statin therapy often showed increased overall survival and better cancer-free survival (P <0.0001) it is evident that cholesterol levels after heart transplantationpatients with statin drugs will make cancer-free survival rate was significantly higher (P <0.0001), and not consider the level of cholesterol, statins after heart transplantation in patients with cancer-free survival increased significant (P = 0.96). Use of statin therapy but can not completely avoid the occurrence of side effects, these side effects including Froelich warning included rhabdomyolysis, research group, said: "These data need long time to come randomized clinical trial to further validate.